Atrial fibrillation (AF) is the most common arrhythmia encountered in acute medical practice. One-third of hospitalizations for cardiac rhythm disturbances are attributed to AF, with increasing rates in the past decade. Significant morbidity and mortality, including 15% to 20% of all ischemic strokes and 20% of all strokes, result from AF. The overall mortality rate for patients with AF is approximately double that for patients in normal sinus rhythm. Atrial flutter (AFL) has many clinical aspects that are similar to AF, AF and AFL have same management strategies in emergency settings. The major goals of treatment include alleviation of the associated symptoms and/or hemodynamic disturbance, reduction of the risk of systemic thromboembolism, reduction in hospital length of stay. The very large scaled AFFIRM and AF-CHF clinical trials compared rate and rhythm control (cardioversion), but did not explore the optimal management for recent-onset AF/AFL patients presenting to the emergency department (ED) with in 48 hours of symptoms. Although international standard guidelines are available, AF treatment in ED is still heterogeneous in terms of the management strategy (rate or rhythm) chosen. National based guidelines or consensus documents specific to ED management of AF has recently been developed and published in order to solve this problem. Aim of this review is to give detailed information for ED team about echocardiographic criterias supporting cardioversion (CV) of AF, CV procedure itself and new antiarrhythmic and oral anticoagulant drugs by adhering to the guidelines.
Introduction
Atrial fibrillation (AF) is the most common arrhythmia encountered in acute medical practice, occurring in 3.3%-10% of emergency admissions [1] [2] [3] [4] . In some of these cases, AF is longstanding and/or incidental to clinical management, but more often AF has developed acutely as either the primary clinical problem or as a complication of another acute (pneumonia, myocardial infarction, septicaemia, pulmonary embolism, exacerbations of chronic obstructive pulmonary disease etc) or chronic (valvular heart disease, hypertension, heart failure, cardiomyopathies, etc) diseases. One-third of hospitalizations for cardiac rhythm disturbances are attributed to AF, with increasing rates in the past decade. Significant morbidity and mortality, including 15% to 20% of all ischemic strokes and 20% of all strokes, result from AF. Patients with nonvalvular AF have 5% average risk of ishemic stroke per year which is 2 to 7 times of the population without AF. The overall mortality rate for patients with AF is approximately double that for patients in normal sinus rhythm (SR) [5, 6] . AF has increasing prevalance and negative impact on quality of life and health care expences. AF is associated with many causes and comorbidities [5, 6] . Atrial flutter (AFL) has many clinical aspects that are similar to AF (ie, underlying disease, predisposing factors, complications, medical management), AF and AFL have same management strategies in emergency settings.
In the emergency department (ED), physicians often manage patients with either recentonset [first detected or recurrent (presence of ≥2 episodes)] or those with permanent AF/AFL. However, it may not be possible to differentiate between a self-limiting attack of "paroxysmal AF" (expected to convert spontaneously to SR within 7 days), or the onset of "persistent AF" (sustained beyond 7 days or SR will only be restored by electrical or pharmacological cardioversion (CV)) if this is the patient's first episode [5] [6] [7] [8] . The major goals of treatment include alleviation of the associated symptoms and/or hemodynamic disturbance, reduction of the risk of systemic thromboembolism, reduction in hospital length of stay. For clinicians, determining management in individual cases can appear complex and confusing because the available therapeutic options include electrical CV (immediate or interval) with or without maintenance antiarrhythmic drugs OR pharmacological CV with intravenous or oral agents OR pharmacological rate-control AND anticoagulation (parenteral or oral) according to guidelines. In the case of permanent AF/AFL or long-standing persistant AF/AFL (>1 year) which usually leads to permanent AF, CV has previously failed or clinical judgment has led to a decision not to pursue CV, ED management focuses on rate control, anticoagulation and treatment of underlying conditions. Management strategies for recent-onset paroxysmal or persistent AF/AFL includes anticoagulation and rate or rhythm control [5] [6] [7] [8] . The very large scaled AFFIRM and AF-CHF clinical trials compared rate and rhythm control, but did not explore the optimal management for recent-onset AF/AFL patients presenting to the ED with in 48 hours of symptoms [9] [10] . Although international standard guidelines are available, AF treatment in ED is still heterogeneous in terms of the management strategy chosen [11] [12] [13] [14] [15] [16] [17] . According to results of many clinical trials showing disparities in management of AF in ED, national based guidelines or consensus documents specific to ED management of AF has recently been developed and published in order to solve this problem [18] [19] . Inspite of the fact that these guidelines are good guidance to clinical practice, information about patient's echocardiographic suitability criterias to CV and CV procedure itself are not well described. Aim of this review is to give detailed information The incidence of stroke in non-valvular AF is 4-5% globally per year, but varies greatly with the thromboembolic risk factors involved. Thromboembolic risk score CHA2DS2-VASc is the best known and practical and recommended by guidelines (Table 2 ) [20] . Of these risk factors, the most important is a history of stroke, TIA or systemic arterial embolism, with a relative risk of 2.5 to 2.9 and an annual incidence of stroke of 12%. Advanced age is second in importance. It is estimated that as from the age of 65 years, the relative risk of developing thromboembolic events increases each decade from 1.4 to 1.8 [19, 20] If total CHA 2 DS 2 -VASc risk score is calculated as 9, there is 15.2% annual adjusted stroke rate risk. Antithrombotic therapy according to CHA 2 DS 2 -VASc risk score is shown in Figure 2 through recommendation by updated 2012 ESC guideline [20] . Decision-making for thromboprophylaxis needs to balance the risk of stroke against the risk of major bleeding, especially intracranial hemmorrhage, which is the most feared complication of anticoagulation therapy and confers a high risk of death and disability. HAS-BLED score which is a formal bleeding risk assessment (Table 3) is recommended for all patients with AF, and in patients with a HAS-BLED score≥3, caution and regular review are appropriate, as well as efforts to correct the potentially reversible risk factors for bleeding. HAS-BLED score should not be used to exclude patients from oral anticoagulant (OAC) therapy but allows clinicians to make an informed assessment of bleeding risk and, importantly, makes them think of the correctable risk factors for bleeding [6, 20] . Target international normalized ratio (INR) is between 2.0 to 3.0 in nonvalvular AF patients anticoagulated with vitamine K antagonists (VKAs) [20] .
The incidence of stroke in patients with AF and mechanical prosthetic valves or valvular heart diseases [rheumatic/degenerative/myxamatous (especially mitral valve diseases)] is about 17%. Thereby, AF requires life-long anticoagulation therapy in patients with valvular heart disease. VKAs (Acenocoumarol, warfarin, phenprocoumon) are the only drugs approved for thromboprophylaxis in these patients [21, 22] Target INR is between 2.0-3.0 in patients valvular heart (except prosthesis) disease with AF [21, 22] . Recommended level of anticoagulation (INR level) in patients with prosthetic valves in the presence of AF is summarized in Table 4 [21, 22] . In ESC/EACTS guideline, the addition of aspirin 75 to 100 mg once daily to therapeutic warfarin is recommended for all patients with mechanical heart valves and those patients with biological valves ( e.g. bioprosthesis) who have risk factors (AF, previous thromboembolism, LV dysfunction EF<35% and hypercoagulable condition) [21] . But in ACC/AHA guideline addition of low-dose aspirin should be considered in patients with a mechanical prosthesis and concomitant atherosclerotic disease or after thromboembolism despite adequate INR [22] .
The pro-embolic tendency increases markedly after CV, if it is spontaneous or pharmacological or electrical, especially when the period of AF before CV is prolonged [23, 24] . After CV, risk of thrombo-embolism due to post-CV left atrial/left atrial appendage (LAA) dysfunction (so-called 'atrial stunning') persists up to 3 months [25] . Anticoagulation in pre-CV and post-CV periods is crucial and discussed more detailed later in the passage.
Arrhyhtmia management strategies in AF
Two different strategies exist for the management of cardiac rhythm in patients with AF. The first entails allowing AF to persist while ventricular rate is controlled. The second is CV and attempting to maintain SR with antiarrhythmic drugs (Figure 1 ) [26] . Goals of the both strategies are to alleviate symptoms, improve functional capacity and quality of life and reduce morbidity/mortality associated with AF/AFL by preventing tachycardiainduced cardiomyopathy and reduce hospitalization/admission rates [5] [6] [7] [8] .
Heart rate control strategy aims to maintain a ventricular rate that protects the patient from consequences of tachycardia. Target ventricular rate control in the absence of accessory pathway (pre-excitation syndrome) can be obtained by atriventricular nodal conduction slowing drugs (Table 5) . Initial target ventricular rate is <100 bpm at rest (lenient rate). If complaints persist despite lenient rate achievement, strict rate control (<80 bpm at rest and <110 bpm during moderate exercise) should be substituted. In case of failure to obtain target ventricular heart rate with drug therapy, atriventricular node ablation and pacemaker implantation can be considered or SR restoration (rhythm control) can be attempted in the presence of supportive clinical and echocardiographic factors (Table 6 ) [6, [18] [19] [20] .
Rhythm control strategy targets SR restoration by pharmacological CV (antiarrhythmic drugs)±electrical CV and maintenance by antiarrhythmic drugs (Table 7) . This strategy is usually considered for patients with paroxsymal or persistant AF in the presence of favourable clinical and echocardiographic parameters (Table 6) [7, 8, 19, 20] . These parameters predict high possibility of staying in SR after CV.
AFFIRM and AF-CHF clinical trials compared rate and rhythm control did not demonstrate significant difference in terms of mortality and morbidity [9] [10] . In clicinal practice, it is more practical and easy to choose rate control strategy for physicians [11, 12] . But it should not be forgotten that these trials did not explore the optimal management for recent-onset AF/AFL patients presenting to the ED with in 48 hours of symptoms. Besides that current guidelines recommend rhythm control as a first line strategy for resent onset AF and suggest not considering heart rate control strategy as an alternative to exclusive control of the rhythm in patients with favourable clinical and echocardiographical factors for attemping SR restoration [6, [18] [19] [20] . Antiplatelet therapy with aspirin plus clopidogrel or less effectively aspirin only, should be considered in patients who refuse any OAC, or cannot tolerate anticoagulants for reasons unrelated to bleeding. Solid line=best option; dashed line= alternative option; CHA2DS2-VASc=see Table 2 ; HAS-BLED score=see Table 3 ; Lone AF=AF without overt structural heart disease, and defined by a normal clinical history and examination, ECG, chest X-ray and, more recently, the echocardiogram; NOAC, novel oral anticoagulant (dabigatran, rivaroxaban, apixaban); OAC, oral anticoagulant; Valvular AF=AF related to rheumatic or Hypotension, bradicardia, pulmonary toxicity, hepatotoxicity, photosensitivity, corneal deposits, skin discoloration, hypo/ hyperthyroidism, polyneuropathy, optic neuropathy, interaction with acenocoumarol /warfarin, bradycardia, QT/QTc prolongation, torsades de pointes (rare). .Diltiazem (iv) could be used in acute setting of heart failure for ventricular control of AF. But routine oral administration of diltiazem/verapamil increases mortality in heart failure patients; ( c ).According to current guidelines digoxine iv use for heart rate control can be given to heart failure patients. Caution should be taken to give long-time therapy because a recent analysis of the AFFIRM trial showed an overall 41% increase in all-cause mortality in patients taking digoxin vs those not taking digoxin. The increase in all-cause mortality was consistently observed in men and women and in patients with and without underlying heart failure [27]; ( d ). A caution should be taken for administration of amiodarone in heart failure patients for heart rate control if duration of AF and effective thromboprophylaxis situation is not known. Because it can cardiovert rhythm to SR. It is generally recommended for critically ill patients; ( e ). Onset of effect of amiodarone is <30 min if administered iv route and 1-3 weeks for oral route [28] ; AV. atrioventricular; NA. not applicable.
Cumhuriyet Tıp Dergisi
Cumhuriyet [32] Right atrial size >37mm Preserved LAA peak emptying velocity [33, 34] .
LAA ejection fraction <30% [35] Higher early diastolic strain rate of basal LA [32] Moderate to severe rheumatic valve diseases iLAV. Indexed left atrial volume; HT. Hypertension; LA. Left atrium; LAA. Left atrial appendage; SR. Sinus rhythm. Table 6 
Management of recent-onset AF/AFL in the ED
Initial management; in all patients presenting to the emergency department with acute AF, immediate provision of supplementary oxygen, establishment of an intravenous line, continuous electrocardiographic monitoring, blood pressure and 12 lead ECG is mandatory. In the emergency department assessment of AF (Table 8) : Its duration, classification, onset date, date of discovery of AF, frequency, precipitating factors and symptoms should be determined. Special attention should also be paid to the diseases in etiology and also investigate ECG for the signs of left ventricular hypertrophy, preexcitation, bundle branch block, prior myocardial infraction and measure QRS and QT/Qtc interval, and investigate chest X ray for the signs of pulmonary diseases and structural heart diseases [40, 41] .
The principles of emergency management of AF are haemodynamic stabilization, prevention of thromboembolism and symptom relief. These goals are achieved by a three part approach to management: thromboprophylaxis, acute rate control and acute rhythm control or CV of AF to SR. CV of AF to SR can be obtained by scheduled emergent electrical CV or emergent/urgent medical (pharmacological) CV by antiarrhythmic drugs and facilitated or pharmacological enhanced (medical plus) electrical CV. 
Treatment of acute precipitants or reversible underlying dieases and distrubances
In some cases the AF has been clearly triggered by another condition, most commonly respiratory tract infection or other sepsis, general anaesthesia, acute pericarditis or myocardial infarction/ischaemia. Sometimes the precipitant (e.g. pneumonia) may require treatment in its own right and if possible CV should be deferred until after it has resolved to reduce the risk of recurrent AF [5] [6] [7] [8] . So, before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of AF (Table 1) is recommended [47] .
Cardioversion of AF/AFL in ED
CV may be achieved by means of drugs or electrical shocks. Drugs were commonly used before electrical CV became a standard procedure [5] . The clinical presentation of acute AF depends on a number of factors, particularly ventricular rate, loss of AV synchrony, cycle length irregularity, and the presence of underlying cardiac disease. The resulting spectrum of symptomatology is broad. Some patients are completely asymptomatic. More often they complain of palpitation, dyspnoea, or weakness, possibly associated with chest discomfort or lightheadedness, but the attack is still reasonably well tolerated. In a minority of cases AF is poorly tolerated due to severe angina or hemodynamic decompensation, i.e. pulmonary oedema, hypotension or circulatory collapse with syncope (rarely). It would be unusual for acute AF to cause significant hemodynamic instability in the absence of structural heart disease, particularly impaired LV function and/or abnormal compliance (e.g. left ventricular hypertrophy, acute myocardial infarction, etc.), or valvular problems such as mitral stenosis or aortic stenosis. Immediate electrical CV should be considered AF causing hemodynamically instability without considering its duration and classification, supportive clinical or echocardiographic parameters, antiarrhythmic drugs and also patient's anticoagulation status ( Figure 3 ) [6, 20] . But, in the meanwhile thromboprophylaxis should be initiated. Immediate electrical CV is also recommended for AF involving preexitation when antegrade conduction via accessory pathway is very fast (Figure 4 ). Because this situtation carries very high risk of rapid progression to ventricular tachycardia/fibrillation and abrupt hemodynamic compromise [44] .
Patients presenting within 48 hours of the onset of AF can be offered immediate pharmacological or electrical CV with heparin (LMWH or unfractionated heparin) ( Figure 3 ). CV of AF more than 48 hours after onset is associated with 5-7% risk of embolic events. Anticoagulation for 3-4 weeks prior to CV will reduce this risk to 0-1.6%. The risk of thromboembolism is due to both pre-CV left atrial thrombus and "atrial stunning" following restoration of SR. Early electrical or pharmacological CV may be performed if TOE has excluded left atrial thrombus but must be followed by full anticoagulation for 4 weeks to prevent de novo thrombus formation due to atrial stunning. If TOE showed the presence of thrombus in left atrial or left atrial appendage, rate control strategy should be chosen with therapeutic oral anticoagulation for 3 weeks. If trombus resolution is seen at TOE after 3 weeks, CV should be performed. But in the case of thrombus persistance at TOE, treatment should be long term oral anticoagulation and rate control [6, 20] . 
Electrical cardioversion of AF/AFL in ED
Electrical CV or direct-current CV involves delivery of an electrical shock synchronized with the intrinsic activity of the heart by sensing the R wave of the ECG to ensure that electrical stimulation does not occur during the vulnerable phase of the cardiac cycle. Electrical CV is used to normalize all abnormal cardiac rhythms except ventricular fibrillation. The term defibrillation implies an asynchronous discharge, which is appropriate for correction of ventricular fibrillation because R-wave synchronization is not feasible, but not for AF [5] . Electrical CV success rates vary from 75 to 93%. They are inversely related to the AF duration, chest wall impedance, and left atrial size [48] [49] [50] [51] [52] . Indeed, success rates vary according to the point in time that success is defined. In one series of 1.838 eletrical CV, success rates, when the duration of AF was <30, 30 to 90, 90 to 180, and >180 days was 84, 78, 77, and 66 percent, respectively.53 When AF has been present for more than five years, success rates are only approximately 50 percent [50] . Indications and contraindications of AF/AFL is given in Table 9 [5, 6, 54, 55] . Technique Electrical CV should be performed with the patient in a fasting state under adequate sedation for elective cases. Drugs chosen for sedation should have short acting effect which produce conscious sedation and also least effect on cardiovascular system while allowing rapid recovery. Oxygen saturation and electrolytes should be normal and anticoagulation status monitored. Continous O 2 flow via nasal cannulea or mask should be given before and after electrical CV, duration of O 2 therapy belongs to patient saturation status. But, O 2 flow must be stopped or removed at least from 1m from the patient's chest during CV to prevent fire [5, 42, 43, 46] . External pacing pads may be used for both CV and for prophylaxis of asystole or bradycardia if ensue after electrical CV or if sick sinus syndrome is suspected [56] .
Success of electrical CV depends on adequacy of delivered current flow through the heart. The major determinants of adequacy of delivered current are: The nature of the shock waveform (mono or biphasic), level of delivered energy. In terms of shock waveform, both monophasic and biphasic waveforms are used [42, 43, 46] . Currently, most evidence favors the use of biphasic external defibrillators due to their categorically lower energy requirements and greater efficacy [57] . Furthermore, fewer shocks are required, thereby potentially reducing procedure times and thus, requirements for intravenous sedation. A lower incidence of skin burns and less skeletal muscle damage have also been reported. Additionally biphasic waveforms result in fewer post-shock arrhythmias, and a shorter period of myocardial stunning [58] . Currently, two conventional positions (anterolateral and anteroposterior) are commonly used for electrode placement. Several studies have shown that anteroposterior electrode placement is more effective than anterolateral placement. If initial shocks are unsuccessful for terminating the arrhythmia, theelectrodes should be repositioned and CV repeated [6] .
In the presence of pacemaker or implantable cardioverter defibrillator, the electrode paddle should be at least 8cm from the pacemaker battery, and the anteroposterior paddle positioning is recommended. Biphasic shocks are preferred because they require less energy for AF termination. In pacemaker-dependent patients, an increase in pacing threshold should be anticipated. These patients should be monitored carefully. After CV, the device should be interrogated and evaluated to ensure normal function [6] . The amount of energy needed for initial attempts of electrical CV has been controversial. Once satisfactory synchronisation is obtained, sedation or anaesthesia is initiated, and a shock is delivered. After shock delivery, if CV is unsuccessful, CV with higher energy is attempted. This can be repeated until the arrhythmia terminates or the decision is made to abandon electrical CV. Initial energy requirements are usually ≥200 joules for monophasic waveform and ≥100 joules for biphasic waveform, with possibly more being required in obese patients and long-standing AF. The initial energy may be lower for CV of AFl, usually the initial energy level for successful CV is 50 joules with a biphasic defibrillator and 50-100 joules with a monophasic defibrillator [5, 6] . But, in the hemodynamic instability condition, electical CV should be performed with maximal energy of the present defibrillator [42, 43, 46] .
Complications
The risks and complications of electrical CV are associated primarily with thromboembolic events, post-CV arrhythmias, and the risks of general anaesthesia. Thromboembolic events have been reported in about 3% to 5% of patients who did not receive anticoagulation before CV, whereas it is only 0% to 1% by adequate anticoagulation or by exclusion of left atrium thrombi before the procedure [59, 60] . Skin burns are a common complication. In patients with sinus node dysfunction, especially in elderly patients with structural heart disease, prolonged sinus arrest without an adequate escape rhythm may occur. Dangerous arrhythmias, such as ventricular tachycardia and fibrillation, may arise in the presence of hypokalaemia, digitalis intoxication, or improper synchronization (R on T phenomenone). The patient may become hypoxic or hypoventilate from sedation, but hypotension and and pulmonary oedema are rare [5, 6] . But, over-the-night stay is generally recommended. As an initial treatment may be considered in order to initiate a long-term rhythm control management strategy for patients with recent-onset AF within 48h of onset by patient/physcian choice.
Elective electrical CV
As an initial treatment may be considered in order to initiate a long-term rhythm control management strategy for patients with recent-onset AF over 48h of onset when TOE has excluded LAA thrombus by patient/physcian choice. Enhanced / facilitated elective electrical CV Which is electrical CV after pretreatment with antiarrhythmic drugs (amiodarone, flecainide, propafenone or ibutilide) in order to enhance success of electrical CV and prevent recurrent AF, should be considered for patients with recent-onset AF within 48h of onset or over 48h if thrombus exluded at TOE. Electice electrical CV Should be considered in order to to initiate a long-term rhythm control management strategy after antiarrhythmic drug failure to restore SR in patients with recent-onset AF within 48h of onset or over 48h if thrombus exluded at TOE. Contraindications Known atrial thrombus and no emergent indication for CV. In the presence of digitalis toxicity. Severe electrolyte imbalance (e.g. hypokalemia) or hyperthyroidsm and no emergent indication for CV. Frequent repetition of direct-current CV is not recommended for patients who have relatively short periods of SR between relapses of AF after multiple CV procedures despite prophylactic antiarrhythmic drug therapy. In the presence of doubt about underlying rhythm (e.g multifocal atrial tachycardia) and no emergent indication for CV [43] [44] [45] . Elective electrical CV without adequate anticoagulation. Elective electrical CV in patients who can not be safely sedated.
Pharmacological cardioversion of AF/AFL in ED
Pharmacological CV should be considered to hemodynamically stable patients (Table  10 ). The conversion rate with antiarrhythmic drugs is lower than with electrical CV, but does not require conscious sedation or anaesthesia, and may facilitate the choice of antiarrhythmic drug therapy to prevent recurrent AF. Most patients who undergo pharmacological CV require continuous medical supervision and ECG monitoring during the drug infusion and for a period afterwards (usually about half the drug elimination half-life) to detect proarrhythmic events such as ventricular proarrhythmia, sinus node arrest, or atrioventricular block. Several agents are available for pharmacological CV (Table 7 ) [5, 6] . Antiarrhythmic drug choice is based on patients characteristics; presence or absence of structural heart disease and antiarrhythmic drug features; side effects, success rates, contraindications (Table 7, Table 11 , Figure 3 ). 
Indications
Pharmacological CV as an initial treatment may be considered in order to initiate a long-term rhythm control management strategy for patients with recent-onset AF within 48h of onset by patient/physcian choice. Pharmacological CV as an initial treatment may be considered in order to initiate a long-term rhythm control management strategy for patients with recent-onset AF over 48h of onset when TOE has excluded LAA thrombus by patient/physcian choice. Pharmacological CV should be considered in order to to initiate a long-term rhythm control management strategy after electrical CV failure to restore SR in patients with recent-onset AF within 48h of onset or over 48h if thrombus exluded at TOE Pretreatment with antiarrhythmic drugs (amiodarone, flecainide, propafenone or ibutilide) in order to enhance success of electrical CV (enhanced / facilitated elective electrical CV) and prevent recurrent AF, in patients patients with recent-onset AF within 48h of onset or over 48h if thrombus exluded at TOE. Contraindications a Known atrial thrombus Severe electrolyte imbalance (e.g. hypokalemia) or hyperthyroidism Pharmacological CV without adequate anticoagulation ( a ). Antiarrhythmic drug specific contraindications and cautions are described in Table 7 . These contraindications are general considerations to all antiarrhyhtmic drugs.
Amiodarone is a class III antiarrhythmic drug. Results of many clinical trials showed that the efficacy of amiodarone ranged from 34% to 69% with bolus (3 to 7mg/kg body weight) regimens and 55% to 95% when the bolus was followed by a continuous infusion (900 to 3000mg for the first 24h). Predictors of successful conversion were shorter duration of AF, smaller LA size, and higher amiodarone dose. Amiodarone was not superior to other antiarrhythmic drugs for conversion of recent-onset AF but was relatively safe in patients with structural heart disease, including those with LV dysfunction and coronary artery disease for whom administration of class IC drugs (flecainide, propafenone) is contraindicated [5, 6] . Class IC drugs were more effective than amiodarone in converting AF when analyzed for the first 2hr after start of therapy, for the first 3 to 5hr, and for the first 6 to 8hr (66% SR in the amiodarone group vs. 71% in the class IC group). At 24hr, however, no significant difference persisted between the various drugs [61] . Particularly if one aims at rapid restoration of SR, amiodarone appears to be less effective than class IC drugs for the pharmacological CV of AF. The complex pharmacokinetic and pharmacodynamic profile of amiodarone seems to be responsible for its somewhat delayed onset of action [5, 6, 61] .
Flecainide administered orally or intravenously was effective for CV of recent-onset AF in placebo-controlled trials. The success of a single oral loading dose (300mg) for CV of recent-onset AF ranged from 57% to 68% at 2 to 4h and 75% to 91% at 8h after drug administration. Single oral loading and intravenous loading regimens of flecainide were equally efficacious, but a response usually occurs within 3h after oral administration and 1h after intravenous administration. Arrhythmias, including AFl with rapid ventricular rates and bradycardia after conversion, are relatively frequent adverse effects [5, 6, 62] .
Propafenone is an effective antiarrhyhthmic drug in converting recent-onset AF to SR. Within a few hours of intravenous administration, the expected conversion rate was between 41 and 91%. The corresponding early conversion rates in placebo treated patients were 10-29%. Propafenone has only a limited efficacy for conversion of persistent AF and for AFl. Similar to flecainide, propafenone should be avoided in patients with underlying heart disease involving abnormal LV function and ischaemia. In addition, owing to its weak b-blocking properties, propafenone should be avoided in severe obstructive lung disease. The time to conversion varies from 30 min to 2h. Propafenone is also effective if administered orally (conversion between 2 and 6h). Because of proarrhythmia risk, both flecainide and propafenone is contraindicated in marked left ventricular hypertrophy (wall thickness ≥1.4cm) [5, 6, 62] . Ibutilide is an class III antiarrhythmic drug. Efficacy of conversion rates within 90 min is about 50% in several well-designed randomized studies, placebo controlled or with a control group of drugs with known little effect. The time to conversion is 30 min. The most important side effect is polymorphic ventricular tachycardia, most often nonsustained, but electrical CV may be needed, and the QTc interval is expected to increase by 60ms. Ibutilide is, however, more effective for conversion of AFl than AF [5, 6, 38] . Vernakalant is a novel agent, which acts preferentially in the atria by blocking several ion channels, resulting in prolongation of atrial refractoriness and rate-dependent slowing of atrial conduction, but has little impact on currents involved in ventricular repolarization [21, 39] . Vernakalant is not classified in Vaughan-Williams class. Vernakalant has a rapid onset of action and a mean elimination half-life of 3-5 hours. The most common side effects of vernakalant were taste alterations (30%), sneezing (16%), paraesthesiae (10%), and nausea (9%), which usually resolved within 5-15 minutes. Serious adverse events were reported at similar rates for vernakalant and placebo (4.1% vs. 3.9%). Transient hypotension occurred in about 5-7% of patients treated with vernakalant, the blood pressure returned to baseline within 15-20 minutes after cessation. Hypotension within the first 2 hours was most common in patients with heart failure (16.1%), leading to discontinuation of treatment in 2.9%. Vernakalant is effective in CV of patients with AF≤7 days or AF≤3 days after cardiac surgery and provides a rapid antiarrhythmic effect of converting approximately 50% of patients within 90 minutes after the start of treatment and a median time to conversion of 8-14 minutes. Vernakalant is administered as a 10-minute infusion of 3mg/kg and, if AF persists after 15 minutes, a second infusion of 2mg/kg can be given [20, 39] .
Vernakalant has a satisfactory safety profile in patients with mild-to-moderate heart disease, including ischaemic heart disease, but should be used with caution in hemodynamically stable patients with NYHA class I and II heart failure, because of increased risk of hypotension and non-sustained ventricular arrhythmias in these patients. Vernakalant is contraindicated in patients with hypotension (systolic blood pressure <100 mmHg), recent acute coronary syndromes (within 30 days), NYHA class III and IV heart failure, severe aortic stenosis, and QT interval prolongation (uncorrected QT. 440ms). In direct comparison, vernakalant was significantly superior to intravenous amiodarone in restoration of SR within 90 min (51.7% vs. 5.2%; P<0.0001) and within 4 hours after infusion (54.4% vs. 22.6%; P<0.0001). Meta-analysis of the efficacy of vernakalant showed that patients were 8.4 times more likely to convert to SR within 90 minutes after vernakalant infusion, than on placebo or amiodarone (95%CI 4.4-16.3), without excess risk of serious adverse events (risk ratio 0.91; 95% CI 0.6-1.36) [21, 39] . Clinical trials accessing efficacy of vernakalant are summerized in Table 12 [39]. 
Enhanced or facilitated electrical CV
Enhanced or facilitated CV is the procedure of antiarrhythmic therapy before standart electrical CV. Pretreatment or repeat treatment with antiarrhythmic drugs such as ibutilide, amiodarone, sotalol, propafenone or flecainide increases the likelihood of restoration of SR and helps prevent recurrent AF. Enhanced efficacy may involve decreasing the energy required to achieve CV, prolonging atrial refractory periods, and suppressing atrial ectopy that may cause early recurrence of AF [5, 6] . Although not without risk, the administration of antiarrhythmic drugs before electrical CV may have a beneficial effect on the different time-dependent types of CV outcomes. Shock failure can be prevented by ibutilide. In 100 patients with persistent AF, placebo and intravenous ibutilide, administered 10 min before electrical CV were compared. Electrical CV had a 100% success rate in the ibutilide-pretreated patients compared to 72% in the placebo group. It is noteworthy that in all the patients in the placebo group in whom CV initially could not restore SR, resumption of SR was obtained when ibutilide was given before a second CV attempt [69] . The selection of the appropriate antiarrhythmic drug to be administered before the electrical CV depends not only on the type of the time-dependent recurrence but also on the presence of structural heart disease [5] .
Optimal cardioversion in ED? Electrical or pharmacological
Rate control drugs were commonly used before CV became a standard procedure. Recent trial showed that use of rate control medication before electrical CV of recent-onset AF or AFl in the emergency department is associated with reduced success rates, but no effect on pharmacological CV [70] . The development of new drugs has increased the popularity of pharmacological CV, but the disadvantages include the risk of drug-induced torsades de pointes or other serious arrhythmias. Moreover, pharmacological CV is less effective than direct-current CV when biphasic shocks are used. The disadvantage of electrical CV is that it requires conscious sedation or anesthesia, which pharmacological CV does not. There is no evidence that the risk of thromboembolism or stroke differs between pharmacological and electrical methods of CV. The recommendations for anticoagulation are therefore the same for both methods [5, 6] .
Is cardioversion feasible?
The chances of restoring and maintaining SR are inversely related to the duration of AF. CV may not usually be attempted if patients have been in persistent AF for more than 1-2 years. The other major predictor of failure is relapse to AF following previous CVs, particularly if this has occurred despite maintenance antiarrhythmic drug therapy. By contrast, advanced age and structural heart disease are often said to be relative contraindications to CV, although there is little objective evidence to suggest that the chances of success are markedly reduced by either. On the other side of the equation, the chances of success are beter with AF of short duration and particularly if there has been an acute precipitant that has resolved (e.g. pneumonia, general anaesthesia, etc.). In patients with structural heart disease (valvular, LV systolic dysfunction, LV hypertrophy, etc.), echocardiographic parameters may be considered before attempting CV (Table 6 ) [5, 30, 33] .
Cardioversion resistant patient or immediate reccurent patient
When electrical CV fails, shocks can be repeated at highest energy until the arrhythmia terminates or a decision is made to abandon electrical CV. Repositioning the paddles or trying other positions (anteroposterior or anterolateral) should also be done in case of failure. Furthermore, the double-paddle technique is another alternative as well as pharmacologic facilitated CV: In one study, patients who had AF and had failed 360-J monophasic CV were loaded with amiodarone orally. If repeat 360-J monophasic CV persisted in failing, the patients underwent the double-paddle technique: Two monophasic defibrillators were used with two sets of paddles for each patient; each defibrillator was set for a synchronous shock at the maximum output of 360J; they then were discharged simultaneously, resulting in successful conversion of 13 out of 15 patients [71] . Energy waveform should be changed to biphasic if it is monophasic. Biphasic waveforms may be of special interest in patients who have failed to revert with the use of monophasic waveforms [72] .
Some rate control drugs (e.g verapamil) may be considered in addition to fascilitated electrical CV, because of their enhancement effect also. If echocardiography is not performed, should be performed to rule out significant atrial enlargement or severe valve diseases. Etiologies of AF should be rechecked. After failure of repeated attemps, CV strategy should be abandoned and rate control startegy should be accepted.
Should adjunctive antiarrhythmic drugs be used for maintenance therapy?
Overall, 70-80% of patients revert to AF within 12 months following successful CV if no antiarrhythmic treatment is prescribed. The chances of relapse can be reduced by drug treatment. Amiodarone is the most commonly used drug. However, even amiodarone only reduces the chance of recurrent AF to 20-30% by the end of the first year. Class I agents (flecainide, propafenone, etc.) are seldom prescribed for this purpose in the light of mounting evidence that they increase cardiac mortality, particularly among patients with ischaemic heart disease and heart failure. Dronadarone can be used in the presence of left ventricular hypertrophy, coronary heart disease but not in heart failure. Echocardiography should be performed before deciding which antiarrhythmic drug for rhythm maintenance therapy [5, 6, 20] .
Thromboprophylaxis in pericardioversion period
The pro-embolic tendency increases markedly after CV, be it spontaneous, pharmacological or electrical, especially when the period of AF before CV is prolonged [23, 24] . After CV, risk of thrombo-embolism due to post-CV left atrial/LAA dysfunction (so-called 'atrial stunning') persists up to 3 months [25] . Thromboembolic events have been reported in about 3% to 5% of patients who did not receive anticoagulation before CV, whereas it is only 0% to 1% by adequate anticoagulation or by exclusion of left atrium thrombus before the procedure [59, 60] .
Planning of adequate thromboprophylaxis pre-CV and post-CV is crucial to prevent embolic events. Thromboproplyaxis with heparin (unfractionated heparin or LMWH) should be given before electrical or pharmacological CV in patients with recent-onset AF within 48h of onset or over 48h if thrombus exluded at TOE [5, 6, 20] . If unfractionated heparin is chosen, therapeutic range for the aPTT should be kept between 1.5 to 2.5 times of the normal value. Unfractionated heparin has rapid onset advantage over LMWH.
Intravenous LMWH has more rapid onset of action than subcutaneous (sc) LMWH. Enoxaparin activity, as measured by anti-Xa levels, achieves peak effect within 10 minutes of an iv injection, irrespective of whether patients are receiving additional medications. For an enoxaparin dose of 1mg/kg iv, the time to subtherapeutic levels is 4 hours [73] . After a sc injection of enoxaparin, the peak time to effective anticoagulation is delayed such that maximum anti-Xa activity levels are not seen until 3-5 hours after drug administration [74] . So, if rapid onset of anticoagulation is desired, either UFH iv or LMWH iv should be given. After CV if one of VKAs is chosen, UFH or LMWH should be continued until INR level reached 2.0-3.0. If dabigatran is chosen for anticoagulation, dabigatran should be initiated 1-2 hours before planned dose of heparin. After CV VKA or dabigatran should be continued for 4 weeks post-CV. After 4 weeks, long term anticoagulation should be planned through the patient's risk factor for thromboembolism (Table 2 ) [20, 69] . In patients with valvular AF INR should be in recommended range (Table 4 
Conclusion
AF remains the most common arrhythmia requiring treatment in the ED and is the cause of major morbidity and considerable financial burden. Choosing the appropriate therapy to treat recent-onset AF can be extremely demanding and problematic and recent efforts have been focused on identification of an iv anti-arrhythmic drug that can provide rapid, effective and safe CV of an acute episode. While the currently available antiarrhythmics show moderate efficacy and pose a risk for serious ventricular proarrhythmias, vernakalant, a recently developed relatively atrial-selective multi-channel inhibitor, has consistently proved to be both effective and safe in converting recent-onset AF to SR in randomized clinical trials. Its relatively high atrial selectivity preventing potentially lethal episodes of torsades de pointes as well as its prompt onset of action, offer iv vernakalant a strong advantage over its competitors and constitutes an attractive option for the physician.
Rapid intervention to recent-onset AF is an other important issue in term of preventing structural changes in left atrium thereby persistence of AF. Although long term efficacy of antiarrhyhmic drugs in maintenance of SR after CV is not much satisfactory. Combination of advances in catheter based therapies and antiarrhythmic drugs for AF seems to fill our expectectations.
